Acrivon Reports Strong Q1, Extends Cash Runway, Targets H2 2026 Interim Data for Key Cancer Drug
ACRV sits 88% above its 52-week low of $1.05 on light trading volume (0.2× avg).
Summary
Acrivon Therapeutics reported its first-quarter 2026 financial results, showcasing a strengthened financial position and significant clinical pipeline advancements. The company reported $97.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026, with an additional $7.3 million from subsequent equity financing, extending its cash runway into the third quarter of 2027. This provides a solid financial foundation for upcoming milestones, improving upon the Q2 2027 runway previously reported in the 10-K. Most notably, the registrational intent Phase 2b study for ACR-368 in serous endometrial cancer is progressing, with a prespecified simultaneous interim analysis and data update now targeted for the second half of 2026. Initial data from the study showed a compelling confirmed overall response rate of 52% in serous EC subjects. The ACR-2316 Phase 1/2 study also continues to advance with favorable tolerability and clinical activity. These updates provide clear, near-term catalysts for the stock and demonstrate strong execution on its precision oncology programs.
At the time of this announcement, ACRV was trading at $1.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.4M. The 52-week trading range was $1.05 to $3.56. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.